dual gip/glp-1 receptor agonist The Sustained Effects of a Agonist, NNC0090-2746, in Patients with Type 2 Diabetes Targeting GLP-1, GIP & GCG

People who use Zepbound or Mounjaro, the dual-agonist medications, lose an average of about 20% of their body weight, while those who take Ozempic or Wegovy, the single-agonist drugs, lost an average of about 14% of their body weight

[Google Scholar] 15.Fodden J.H., Read W.O

Thats a significantly higher percentage than most other non-surgical weight loss treatments

: -: #Cagrilintide works via the amylin pathway, distinct from the increasingly common #GLP-1 therapies

Diabetes 69 , 25892602 (2020)

They lower blood glucose levels, slow gastric emptying, lower serum cholesterol and triglyceride levels, reduce liver fat content, decrease the highly inflammatory visceral fat, enhance microvascular (!) blood flows in the muscle tissue, reduce muscle-produced inflammation, microglial activation (neuroinflammation), and enhance neuroplasticity